Viatris Inc. announced positive top-line results from VEGA-3, its second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia. Presbyopia is a common condition affecting approximately 90% of adults in the U.S. over the age of 45.
MR-141 successfully met its primary and all secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity without compromising distance vision. This indicates a favorable efficacy profile for the investigational drug.
The safety profile observed in the VEGA-3 trial was consistent with previous clinical studies, with no treatment-related serious adverse events reported. This consistency supports the drug's overall benefit-risk profile.
Viatris is targeting an application to the U.S. Food and Drug Administration (FDA) in the second half of 2025. These positive results reinforce confidence in MR-141 as a potential non-invasive option to support the millions of patients impacted by presbyopia, strengthening Viatris's innovative pipeline in ophthalmology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.